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Abstract
The number of patients who suffer from heart failure is rapidly increasing. In about one‐
third of heart failure patients, conduction delays cause dyssynchronous left ventricular 
contractions, which leads to reduction in left ventricular function, adverse cardiac remod‐
elling and finally increased mortality. Cardiac resynchronization involves simultaneous 
pacing of both ventricles, and improves left ventricular contractile function. Although 
resynchronization does not restore myocardial function, multiple studies have shown 
that cardiac resynchronization therapy improves quality of life, exercise capacity, symp‐
toms of heart failure, left ventricular ejection fraction, morbidity and mortality. The use 
of cardiac resynchronization therapy has increased significantly, since its initial approval 
in 2001, in patients with advanced heart failure.
Keywords: heart failure, cardiac resynchronization therapy, electrophysiologist, left 
bundle branch block, left ventricular function
1. Introduction
The number of patients who suffer from chronic heart failure is rapidly growing. According 
to the 2016 update on heart disease and stroke statistics reported by the American Heart 
Association, an estimated 5.7 million Americans ≥20 years of age have a diagnosis of heart 
failure and projections show that the prevalence of heart failure will increase 46% from 2012 
to 2030, resulting in >8 million people ≥18 years of age with heart failure [1]. In the year of 
2013, heart failure was the underlying cause in >65,000 deaths and contributed to the death 
of >300,000 people [1]. In the same report, there is an estimate that a total cost of over $30 bil‐
lion was used for the treatment of heart failure in 2012 [1]. Direct medical costs attributed to 
68% of this total amount. The lifetime risk of developing heart failure is 20% for adults at the 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
age of 40 years and goes up with age. Acute heart failure consists of one of the most common 
reasons for hospitalization, attributing to over 1 million discharges annually and high 30‐day 
readmission rates (up to 25%) and 1 year (up to 60%) [1]. The prognosis for heart failure is 
poor, with an estimated mortality rate of 50% within 5 years of diagnosis.
2. Cardiac resynchronization therapy (CRT)
2.1. Advent of CRT
An intraventricular conduction delay is found in approximately 20–30% of patients with 
symptomatic heart failure. Conduction delay causes dyssynchronous left ventricular contrac‐
tions, which lead to left ventricular dysfunction, adverse cardiac remodelling and eventu‐
ally high mortality [2–4]. Conduction delay may also lead to mitral valve regurgitation, thus 
increasing symptoms of heart failure. The prevalence of left ventricular dyssynchrony in heart 
failure has been shown to increase with reduced left ventricular ejection fraction and with 
increased QRS width [5–7].
Cardiac resynchronization therapy (CRT), which was first introduced for clinical use in 1996, 
attempts to restore ventricular synchrony in patients who suffer from dilated cardiomyopa‐
thy with a widened QRS complex to improve the mechanical efficiency of left ventricular 
contraction. Since U.S. Food and Drug Administration (FDA) approval, the use of CRT has 
steadily increased [8]. Sridhar and colleagues showed a trend in CRT device implantation in 
the United States [9] (Figure 1).
2.2. Mechanism of CRT
Janaswamy et al. listed the studies which demonstrated that the presence of a bundle branch 
block or other intraventricular conduction delay can worsen heart failure due to systolic dys‐
function by causing ventricular dyssynchrony [10] (Table 1). The rationale for CRT is based upon 
these findings. These acute mechanical benefits of CRT can be accompanied with more chronic 
adaptations that lead to long‐term benefit in the patient who suffers from heart failure [11].
Nowadays, it has been reported that CRT improves quality of life, exercise capacity, symp‐
toms of heart failure by [12–16] left ventricular ejection fraction [17, 18], morbidity and mor‐
tality [18] in patients with moderate to severe left ventricular dysfunction with a wide QRS 
complex. The benefit of CRT in mild to moderate heart failure has also been demonstrated by 
several studies [19–23]. Long‐term beneficial effects on left ventricular function were shown 
by positron emission tomography evaluations, and CRT enhances myocardial forward work 
efficiency at rest in patients with dilated cardiomyopathy and heart failure [24, 25].
CRT improves left ventricular contractile function in patients with heart failure associated 
with left bundle branch block. Improved efficiency from resynchronization pacing is unlikely 
due to the alterations in intrinsic myocyte function. The improvement of ventricular func‐
tion is the result of improved efficiency of the work performed by different regions of the 
wall. Nelson et al. demonstrated that pressure‐volume loops display an increase in loop area 
and width (stroke work and volume, respectively) and a decline in end systolic volume with 
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pacing [25]. In spite of improvements in systolic function, myocardial oxygen consumption 
decreases due to a slight fall in coronary flow as well as transcardiac oxygen gradient.
2.3. U.S. trends in CRT
CRT is now recommended for patients with heart failure due to systolic dysfunction com‐
bined with intraventricular delay. CRT is also recommended in addition to guideline‐directed 
medical therapy, such as angiotensin‐converting enzyme inhibitors, beta blockers, aldoste‐
rone antagonist therapy and implantable cardioverter defibrillators (ICDs) when indicated 
for primary or secondary prevention of sudden cardiac death.
Sridhar et al. used the Nationwide Inpatient Sample database to identify all patients who 
underwent CRT implantation during 2002–2010 [9]. The overall trends in CRT device implan‐
tation, patient characteristics and outcomes were studied in detail and comparisons among 
demographic subgroups were performed. They found that an average of 41,578 CRT device 
implantations was performed per year. There has been a significant increase in the percentage 
of CRTs implanted in patients with advanced age (≥85 years). There were significant differ‐
ences in CRT utilization favouring male and whites compared with female and black patients, 
respectively, in spite of adjustments for rates of heart failure. The highest numbers of implants 
were found in the patient group with moderate comorbidity (48%), followed by mild comor‐
bidity group (39/7%). The overall number of CRT implantations in the severe comorbidity 
group was the lowest (12.3%). However, in the recent years, there has been a significant 
increase in the number of CRT implantation in this category (Figure 2).
Figure 1. The number of CRT device implantation in the United States.
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Trial Inclusion criteria Primary end point Follow‐up Results/conclusion
MIRACLE [12] QRS duration 
≥130 ms, an LV 
end diastolic 
diameter ≥55 mm by 
echocardiography 
and ejection fraction 
(EF) ≤0.35
NYHA symptom 
class, quality of life 
(Minnesota Living 
with heart failure 
questionnaire) and 
exercise capacity
6 months Significant reductions in 
LVEDV (P < 0.001) and LVESV 
(P < 0.001) at 3 months, and 
continued to 6 months, in the 
CRT group compared with 
the control group. Significant 
improvement in EF compared 
with the control group at 
3 months (2.3 vs. 0.6%; 
P < 0.01) and 6 months (3.6 vs. 
0.4%; P < 0.001). Significant 
decrease in severity of MR 
at 3 months (‐2.1 vs. 0.1 cm2 
jet area; P < 0.01) and at 6 
months (‐2.5 vs. 0.5 cm2 jet 
area; P < 0.001). Increase in 
cardiac index from baseline to 
6 months (0.11 L · min‐1 · m‐2; 
P < 0.05).
PATH‐CHF [13] NYHA 
functional class 
III or IV, dilated 
cardiomyopathy of 
any etiology, sinus 
rhythm ≥55 beats/
min, a QRS complex 
duration ≥120 ms in 
at least two surface 
electrocardiographic 
(ECG) leads and a 
PR interval ≥150 ms
Primary end points: 
oxygen uptake 
at peak exercise, 
oxygen uptake at the 
anaerobic threshold 
and the 6‐min 
walking distance. 
The secondary end 
points were changes 
in NYHA functional 
class and quality 
of life.
12 months Oxygen uptake during 
bicycle exercise increased 
from 9.48 to 10.4 ml/kg/min 
at the anaerobic threshold 
(P = 0.03) and from 12.5 
to 14.3 ml/kg/min at peak 
exercise (P < 0.001) with the 
first treatment. From 10.0 
to 10.7 ml/kg/min at the 
anaerobic threshold (P = 0.2) 
and from 13.4 to 15.2 ml/
kg/min at peak exercise 
(P = 0.002) with the second 
treatment. Increase in 
maximal exercise capacity 
from 12.6 to 15.6 ml/kg/
min. Increase in 6‐min walk 
performance from 357 to 466 
m. 2/3 of patients improved 
to NYHA functional class I 
or II.
MUSTIC [14] Severe HF with 
EF < 0.35 as 
measured by 
radionuclides and 
an LV end diastolic 
diameter >60 mm 
NYHA functional 
class III. The 6‐min 
walking distance 
<450 m. QRS 
duration >150 ms. 
AF > 3 months. QRS 
duration >200 ms
6‐min walking 
distance, the 
peak VO2 by 
cardiopulmonary 
exercise test, quality 
of life, NYHA 
class, systolic and 
diastolic blood 
pressure (BP), 
body weight, 
12‐lead surface 
electrocardiogram 
(ECG), 24‐h 
Holter monitoring 
and Doppler 
echocardiography
1 year Significant improvement in 
6‐min walk distance of 20% 
compared with baseline at 6, 
9 and 12 months. Peak VO2 
at 12 months had increased 
by 1.7 ml/min/kg or 11% in 
the SR group and 1.1 ml/kg/
min or 9% in the AF group 
compared with baseline. 
Reduction in the Minnesota 
score of 17 points or 36% in 
the SR group and of 14 points 
or 32% in the AF group. The 
NYHA class improved by 0.7 
in the SR group and 0.8 in the 
AF group.
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Trial Inclusion criteria Primary end point Follow‐up Results/conclusion
MIRACLE ICD [16] 
Combination with ICD
Cardiac arrest 
due to VF or VT, 
or spontaneously 
sustained 
ventricular 
tachyarrhythmia, or 
inducible ventricular 
fibrillation 
or sustained 
ventricular 
tachyarrhythmia, 
NYHA III or IV 
LVEF ≤ 0.35 QRS 
duration ≥130 ms 
LVEDD ≥55 mm
Primary end points: 
NYHA functional 
class, quality‐of‐life 
score and distance 
covered during the 
6‐min walking test.
1, 3 and 6 
months.
Significantly higher median 
improvement in quality of 
life, NYHA functional class 
and distance during 6‐min 
walk in the CRT group 
compared with the control 
group.
RAFT [19] ICD + CRT NHYA class II or III, 
EF <0.30, an intrinsic 
QRS duration of 
120 ms or more or a 
paced QRS duration 
of 200 ms or more, 
sinus rhythm or 
permanent AF 
or flutter with 
a controlled 
ventricular rate (≤60 
beats per minute 
at rest and ≤90 
beats per minute 
during a 6‐min walk 
test) or planned 
atrioventricular‐
junction ablation 
after device 
implantation), 
and planned ICD 
implantation for 
indicated primary 
or secondary 
prevention of 
sudden cardiac death
Primary outcome: 
death from any 
cause or heart 
failure leading to 
hospitalization
The mean 
(±SD) follow‐
up period 
was 40 ± 20 
months for all 
patients and 
44 ± 18 months 
for surviving 
patients
Prolonged time to the 
occurrence of the primary 
outcome in the ICD–CRT 
group (hazard ratio, 0.75; 
95% confidence interval [CI], 
0.64–0.87; P < 0.001). The time 
until death was significantly 
prolonged (relative risk 
reduction, 25%) in the 
ICD–CRT group (hazard 
ratio, 0.75; 95% CI, 0.62–0.91; 
P = 0.003).
COMPANION [29] 
Pharmacologic 
therapy alone, 
pharmacologic + CRV 
with pacemaker, 
pharmacologic + CRT+ 
pacemaker defibrillator
NYHA class III or IV 
HF, LVEF of 0.35 or 
less, QRS interval of 
at least 120 ms and a 
PR interval of more 
than 150 ms, sinus 
rhythm, no clinical 
indication for a 
pacemaker or ICD, 
and a hospitalization 
for the treatment 
of heart failure or 
the equivalent in 
the preceding 12 
months.
primary end point: 
composite of death 
from any cause or 
hospitalization for 
any cause
Median 
duration of 
follow‐up for 
the primary 
end point: 11.9 
months in the 
pharmacologic 
therapy group, 
16.2 months in 
the pacemaker 
group and 15.7 
months in the 
pacemaker 
defibrillator 
group
12‐month rate of death from 
any cause or hospitalization 
for any cause was 68% in the 
pharmacologic therapy group 
as compared with 56% in the 
pacemaker group (hazard 
ratio for the primary end 
point: 0.81) and 56% in the 
pacemaker defibrillator group 
(hazard ratio, 0.80)
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2.4. Outcomes of CRT implantation
The in‐hospital mortality rates associated with CRT implantation is shown in Figure 3.
For an elective CRT procedure, the mean length of stay was 2.81 days and the median was 
1.00 day. The overall in‐hospital mortality following CRT implantation was 0.87%, which has 
decreased significantly from 2003 to 2010 (1.08 in 2003 to 0.70% in 2010; P = 0.03). Mortality fol‐
lowing elective CRT implantation was 0.4% compared with 1.0% with non‐elective CRT implan‐
tations. The mortality was higher in male (0.93%) compared with female (0.71%), and decrease 
in mortality was observed in both male and female. The mortality rate in advanced age group 
(≥85 years) was significantly higher compared with younger population (<85 years). However, 
the mortality rate in the ≥85‐year group has significantly decreased in recent years. Patients with 
Trial Inclusion criteria Primary end point Follow‐up Results/conclusion
MADIT‐CRT [30] ICD 
and CRT
Ejection fraction of 
30% or less, a QRS 
duration of 130 
ms or more, and 
NYHA class I or II 
symptoms
Death from any 
cause or nonfatal 
heart failure events, 
whichever came first
Follow‐up of 
patients in the 
trial averaged 
2.4 years
34% reduction in the risk 
of death or nonfatal heart 
failure (whichever came first) 
among patients in the CRT–
ICD group, as compared 
with those in the ICD‐only 
group. CRT–ICD therapy 
was associated with a greater 
benefit in women (hazard 
ratio, 0.37; 95% confidence 
interval [CI], 0.22–0.61) than 
in men (hazard ratio, 0.76; 
95% CI, 0.59–0.97; P = 0.01 for 
interaction) and in patients 
with a QRS duration of 150 
ms or more (hazard ratio, 
0.48; 95% CI, 0.37–0.64) than 
in those with a QRS duration 
of less than 150 ms (hazard 
ratio, 1.06; 95% CI, 0.74–1.52; 
P = 0.001 for interaction).
REVERSE [31] QRS ≥120 ms and 
LV ejection fraction 
≤0.40, active 55‐mm 
or wider LV end 
diastolic diameter, 
measured by 
echocardiography
Primary end 
point: HF clinical 
composite response
Patients were 
followed at 1, 3, 
6, 12, 18 and 24 
months
Worsening of the HF 
clinical composite response 
in 34 of the 180 patients 
(19%) assigned to CRT ON 
compared with 28 of the 82 
patients (34%) assigned to 
CRT OFF (p = 0.01). LVESVi 
decreased by a mean of 
27.5 ± 31.8 ml/m2 in the CRT 
ON compared with 2.7 ± 25.8 
ml/m2 in the CRT OFF group 
(P < 0.0001). Rates of HF 
hospital stay was 14 of 82 
(17.1%) in CRT OFF patients 
and 13 of 180 (7.2%) CRT ON 
patients
Table 1. Summary of studies of CRT.
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severe comorbidities had significantly higher overall mortality (1.5%) compared with those with 
moderate (0.8%) or mild (0.7%) comorbidities (P < 0.001). However, mortality in all three comor‐
bidity groups has decreased in recent years, most notably in the severe comorbidity group.
In terms of complications associated with CRT implantation, pericardial effusion was found 
in 0.2%, pneumothorax was found in 1.4% and hematoma was found in 3.0% of all CRT 
implantation procedures.
Figure 3. In‐hospital mortality rates associated with CRT implantation stratified by patient characteristics.
Figure 2. Patient comorbidities and CRT implantation. (A) CRT implantation trends stratified according to comorbidity 
categories. (B) CRT devices implanted in patients with severe comorbidities, expressed as a percentage of total CRT 
implants in the United States in each year.
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The overall mean hospital charges accompanied with CRT implantation were reported to 
be $129,098 per implant. Of note, hospital charges for CRT implantation have dramatically 
increased from $111,197 in 2003 to $154,297 in 2010 (P < 0.001). Charges accompanied with 
CRT implantation were higher in male sex, ≥85‐year group, and higher comorbidities com‐
pared with female sex, <85‐year group, and lower comorbidities, respectively.
2.5. Implantation technique of CRT
Electrophysiologists are the main players for the CRT implantation. The CRT implantation 
requires the placement of a left ventricular pacing lead, which is fed onto the epicardial sur‐
face through a venous branch of the coronary sinus (Figure 4). Difficulty with coronary sinus 
cannulation, challenging anatomy of coronary sinus venous tributaries, unacceptable pac‐
ing and sensing thresholds, unavoidable phrenic nerve pacing and lead dislodgement have 
resulted in a 10–20% failure rate associated with left ventricular lead placement [16, 26]. When 
a transvenous lead implantation at desired sites is not achievable, epicardial left ventricular 
leads can easily be placed surgically directly on the lateral or posterolateral wall. Garikipati et 
al. performed a randomized study and reported no difference in the echocardiographic and 
clinical outcomes comparing a conventional transvenous approach versus surgical epicardial 
left ventricular lead placement for CRT [27]. Therefore, surgical approaches are a viable alter‐
native when a transvenous procedure has failed or is not feasible.
Zhang et al. reported that advanced age, male sex, ischemic cause, end‐stage heart failure, 
inadequate electrical delay and absence of mechanical dyssynchrony are regarded as non‐
modifiable risk factors for CRT non‐responders [28]. However, efforts should be made to cor‐
rect modifiable factors, such as suboptimal medical therapy, uncontrolled atrial fibrillation, 
left ventricular lead dislodgement or inappropriate location, loss of biventricular capture and 
lack of device optimization.
Figure 4. A chest X‐ray after a successful CRT implantation.
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3. Conclusions
CRT implantation is a safe procedure that has become safer in higher risk patients. With the 
increase of heart failure patients, CRT plays more and more role in the treatment of heart 
failure. Electrophysiologists should understand the indication, outcomes and procedure tech‐
nique of CRT implantation.
Author details
Takashi Murashita
Address all correspondence to: tmurashita@gmail.com
Heart and Vascular Institute, West Virginia University, Morgantown, WV, USA
References
[1] Writing Group Members, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, 
Cushman M, Das SR, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, 
Isasi CR, Jiménez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, 
Magid DJ, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, 
Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond 
W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB; 
American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart 
disease and stroke statistics‐2016 update: a report from the American heart association. 
Circulation. 2016;133(4):38–360. DOI: 10.1161/CIR.0000000000000350
[2] Baldasseroni S, Opasich C, Gorini M, Lucci D, Marchionni N, Marini M, Campana 
C, Perini G, Deorsola A, Masotti G, Tavazzi L, Maggioni AP; Italian Network on 
Congestive Heart Failure Investigators. Left bundle‐branch block is associated with 
increased 1‐year sudden and total mortality rate in 5517 outpatients with congestive 
heart failure: a report from the Italian network on congestive heart failure. Am Heart J. 
2002;143(3):398–405.
[3] Kawaguchi M, Murabayashi T, Fetics BJ, Nelson GS, Samejima H, Nevo E, Kass 
DA. Quantitation of basal dyssynchrony and acute resynchronization from left or 
biventricular pacing by novel echo‐contrast variability imaging. J Am Coll Cardiol. 
2002;39(12):2052–8.
[4] Shamim W, Francis DP, Yousufuddin M, Varney S, Pieopli MF, Anker SD, Coats AJ. 
Intraventricular conduction delay: a prognostic marker in chronic heart failure. Int J 
Cardiol. 1999;70(2):171–8.
[5] De Sutter J, Van de Veire NR, Muyldermans L, De Backer T, Hoffer E, Vaerenberg 
M, Paelinck B, Decoodt P, Gabriel L, Gillebert TC, Van Camp G; Working Group of 
The Impact of Cardiac Resynchronization Therapy in the Treatment of Heart Failure
http://dx.doi.org/10.5772/66947
65
Echocardiography and Cardiac Doppler of the Belgian Society of Cardiology. Prevalence 
of mechanical dyssynchrony in patients with heart failure and preserved left ventricular 
function (a report from the Belgian multicenter registry on dyssynchrony). Am J Cardiol. 
2005;96(11):1543–8.
[6] Ghio S, Constantin C, Klersy C, Serio A, Fontana A, Campana C, Tavazzi L. Interventricular 
and intraventricular dyssynchrony are common in heart failure patients, regardless of 
QRS duration. Eur Heart J. 2004;25(7):571–8.
[7] Haghjoo M, Bagherzadeh A, Fazelifar AF, Haghighi ZO, Esmaielzadeh M, Alizadeh A, 
Emkanjoo Z, Sadeghpour A, Samiei N, Farahani MM, Sadr‐Ameli MA, Maleki M, Noohi 
F. Prevalence of mechanical dyssynchrony in heart failure patients with different QRS 
durations. Pacing Clin Electrophysiol. 2007;30(5):616–22.
[8] Moynahan M, Faris OP, Lewis BM. Cardiac resynchronization devices: the Food and 
Drug Administration's regulatory considerations. J Am Coll Cardiol. 2005;46(12):2325–8.
[9] Sridhar AR, Yarlagadda V, Parasa S, Reddy YM, Patel D, Lakkireddy D, Wilkoff BL, 
Dawn B. Cardiac resynchronization therapy: US trends and disparities in utilization 
and outcomes. Circ Arrhythm Electrophysiol. 2016;9(e003108):26921376. DOI: 10.1161/
CIRCEP.115.003108
[10] Janaswamy P, Walters TE, Nazer B, Lee RJ. Current treatment strategies for heart fail‐
ure: role of device therapy and lv reconstruction. Curr Treat Options Cardiovasc Med. 
2016;18(9):57. DOI: 10.1007/s11936‐016‐0479‐1
[11] Abraham WT, Hayes DL. Cardiac resynchronization therapy for heart failure. 
Circulation. 2003;108(21):2596–603.
[12] Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer 
M, Clavell AL, Hayes DL, Ellestad M, Trupp RJ, Underwood J, Pickering F, Truex C, 
McAtee P, Messenger J; MIRACLE Study Group. Multicenter InSync randomized 
clinical evaluation. Cardiac resynchronization in chronic heart failure. N Engl J Med. 
2002;346(24):1845–53.
[13] Auricchio A, Stellbrink C, Sack S, Block M, Vogt J, Bakker P, Huth C, Schöndube F, 
Wolfhard U, Böcker D, Krahnefeld O, Kirkels H; Pacing Therapies in Congestive Heart 
Failure (PATH‐CHF) Study Group. Long‐term clinical effect of hemodynamically opti‐
mized cardiac resynchronization therapy in patients with heart failure and ventricular 
conduction delay. J Am Coll Cardiol. 2002;39(12):2026–33.
[14] Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, Garrigue S, 
Kappenberger L, Haywood GA, Santini M, Bailleul C, Daubert JC; Multisite Stimulation 
in Cardiomyopathies (MUSTIC) Study Investigators. Effects of multisite biventricular 
pacing in patients with heart failure and intraventricular conduction delay. N Engl J 
Med. 2001;344(12):873–80.
[15] Higgins SL, Hummel JD, Niazi IK, Giudici MC, Worley SJ, Saxon LA, Boehmer JP, 
Higginbotham MB, De Marco T, Foster E, Yong PG. Cardiac resynchronization therapy 
The Role of the Clinical Cardiac Electrophysiologist in the Management of Congestive Heart Failure66
for the treatment of heart failure in patients with intraventricular conduction delay and 
malignant ventricular tachyarrhythmias. J Am Coll Cardiol. 2003;42(8):1454–9.
[16] Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, Canby RC, 
Schroeder JS, Liem LB, Hall S, Wheelan K; Multicenter InSync ICD Randomized Clinical 
Evaluation (MIRACLE ICD) Trial Investigators. Combined cardiac resynchronization 
and implantable cardioversion defibrillation in advanced chronic heart failure: the 
MIRACLE ICD Trial. JAMA. 2003;289(20):2685–94.
[17] Sutton MG, Plappert T, Hilpisch KE, Abraham WT, Hayes DL, Chinchoy E. Sustained reverse 
left ventricular structural remodeling with cardiac resynchronization at one year is a func‐
tion of etiology: quantitative Doppler echocardiographic evidence from the Multicenter 
InSync randomized clinical evaluation (MIRACLE). Circulation. 2006;113(2):266–72.
[18] Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi 
L; Cardiac Resynchronization‐Heart Failure (CARE‐HF) Study Investigators. The effect 
of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 
2005;352(15):1539–49.
[19] Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol 
G, Birnie DH, Sapp JL, Yee R, Healey JS, Rouleau JL; Resynchronization‐Defibrillation 
for Ambulatory Heart Failure Trial Investigators. Cardiac‐resynchronization therapy for 
mild‐to‐moderate heart failure. N Engl J Med. 2010;363(25):2385–95.
[20] Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA 3rd, Foster E, 
Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W; MADIT‐CRT 
Trial Investigators. Cardiac‐resynchronization therapy for the prevention of heart‐fail‐
ure events. N Engl J Med. 2009;361(14):1329–38.
[21] Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C; REVERSE 
(REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study 
Group. Randomized trial of cardiac resynchronization in mildly symptomatic heart fail‐
ure patients and in asymptomatic patients with left ventricular dysfunction and previ‐
ous heart failure symptoms. J Am Coll Cardiol. 2008;52(23):1834–43.
[22] Abraham WT, Young JB, León AR, Adler S, Bank AJ, Hall SA, Lieberman R, Liem LB, 
O'Connell JB, Schroeder JS, Wheelan KR; Multicenter InSync ICD II Study Group. Effects 
of cardiac resynchronization on disease progression in patients with left ventricular sys‐
tolic dysfunction, an indication for an implantable cardioverter‐defibrillator, and mildly 
symptomatic chronic heart failure. Circulation. 2004;110(18):2864–8.
[23] Veazie PJ, Noyes K, Li Q, Hall WJ, Buttaccio A, Thevenet‐Morrison K, Moss AJ. Cardiac 
resynchronization and quality of life in patients with minimally symptomatic heart fail‐
ure. J Am Coll Cardiol. 2012;60(19):1940–4.
[24] Ukkonen H, Beanlands RS, Burwash IG, de Kemp RA, Nahmias C, Fallen E, Hill MR, 
Tang AS. Effect of cardiac resynchronization on myocardial efficiency and regional oxi‐
dative metabolism. Circulation. 2003;107(1):28–31.
The Impact of Cardiac Resynchronization Therapy in the Treatment of Heart Failure
http://dx.doi.org/10.5772/66947
67
[25] Nelson GS, Berger RD, Fetics BJ, Talbot M, Spinelli JC, Hare JM, Kass DA. Left ven‐
tricular or biventricular pacing improves cardiac function at diminished energy cost 
in patients with dilated cardiomyopathy and left bundle‐branch block. Circulation. 
2000;102(25):3053–9.
[26] Mullens W, Grimm RA, Verga T, Dresing T, Starling RC, Wilkoff BL, Tang WH. Insights 
from a cardiac resynchronization optimization clinic as part of a heart failure disease man‐
agement program. J Am Coll Cardiol. 2009;53(9):765–73. DOI: 10.1016/j.jacc.2008.11.024
[27] Garikipati NV, Mittal S, Chaudhry F, Musat DL, Sichrovsky T, Preminger M, Arshad A, 
Steinberg JS. Comparison of endovascular versus epicardial lead placement for resynchro‐
nization therapy. Am J Cardiol. 2014;113(5):840–4. DOI: 10.1016/j.amjcard.2013.11.040
[28] Zhang Q, Zhou Y, Yu CM. Incidence, definition, diagnosis, and management of the car‐
diac resynchronization therapy nonresponder. Curr Opin Cardiol. 2015;30(1):40–9. DOI: 
10.1097/HCO.0000000000000140
[29] Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo 
L, DeMets D, White BG, DeVries DW, Feldman AM; Comparison of Medical Therapy, 
Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac‐resyn‐
chronization therapy with or without an implantable defibrillator in advanced chronic 
heart failure. N Engl J Med. 2004;350(21):2140–50.
[30] Zareba W, Klein H, Cygankiewicz I, Hall WJ, McNitt S, Brown M, Cannom D, Daubert 
JP, Eldar M, Gold MR, Goldberger JJ, Goldenberg I, Lichstein E, Pitschner H, Rashtian 
M, Solomon S, Viskin S, Wang P, Moss AJ; MADIT‐CRT Investigators. Effectiveness of 
cardiac resynchronization therapy by QRS morphology in the multicenter automatic 
defibrillator implantation trial‐cardiac resynchronization therapy (MADIT‐CRT). 
Circulation. 2011;123(10):1061–72. DOI: 10.1161/CIRCULATIONAHA.110.960898
[31] Daubert C, Gold MR, Abraham WT, Ghio S, Hassager C, Goode G, Szili‐Török T, Linde 
C; REVERSE Study Group. Prevention of disease progression by cardiac resynchroni‐
zation therapy in patients with asymptomatic or mildly symptomatic left ventricular 
dysfunction: insights from the European cohort of the REVERSE (Resynchronization 
reverses remodeling in systolic left ventricular dysfunction) trial. J Am Coll Cardiol. 
2009;54(20):1837–46. DOI: 10.1016/j.jacc.2009.08.011
The Role of the Clinical Cardiac Electrophysiologist in the Management of Congestive Heart Failure68
